Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study

Abstract: We report final analysis results from the PILOT study of lisocabtagene maraleucel (liso-cel) for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Sixty-one adults with R/R LBCL who had received 1 previous line of therapy and met ≥1 hematopoietic stem cell transplantati...

Полное описание

Библиографические подробности

Главные авторы:	Alison Sehgal, Daanish Hoda, Peter A. Riedell, Nilanjan Ghosh, Mehdi Hamadani, Gerhard C. Hildebrandt, John E. Godwin, Patrick M. Reagan, Nina D. Wagner-Johnston, James Essell, Rajneesh Nath, Scott R. Solomon, Rebecca Champion, Edward Licitra, Suzanne Fanning, Neel K. Gupta, Victor A. Chow, Brenda Yuan, Zhi Yang, Ken Ogasawara, Jerill Thorpe, Leo I. Gordon
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2025-08-01
Серии:	Blood Advances
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S247395292500254X
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!